| Bioactivity | JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer[1][2][3]. |
| CAS | 2401867-58-9 |
| Formula | C31H30N8O3 |
| Molar Mass | 562.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rubin E, et al. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int J Mol Sci. 2024 Jan 15;25(2):1064. [2]. Vathiotis IA, et al. Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond. Cancers (Basel). 2023 Feb 17;15(4):1286. [3]. Son J, et al. A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 Apr 15;82(8):1633-1645. |
JBJ-08-178-01
CAS: 2401867-58-9 F: C31H30N8O3 W: 562.62
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) wi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.